Melanoma
Clinical guidelines for managing cutaneous melanoma, understanding surgical margins, and reviewing targeted immunotherapies.
Table of Contents
🧠 Standard of Care & Symptoms
Cutaneous Melanoma is a potentially aggressive type of skin cancer that originates in the pigment-producing melanocytes. While less common than basal or squamous cell carcinomas, it is responsible for the majority of skin cancer-related deaths due to its potential to metastasize.
- The ABCDE Screening Rule:
- Asymmetry: One half of the mole does not match the other.
- Border: Edges are irregular, ragged, notched, or blurred.
- Color: Pigmentation is not uniform, showing shades of brown, black, red, pink, blue, or white.
- Diameter: Larger than 6 millimeters (about the size of a pencil eraser), though melanomas can sometimes be smaller.
- Evolving: The mole is changing in size, shape, color, or is causing new symptoms like itching, bleeding, or crusting.
- Microscopic Staging: Prognosis is heavily dependent on **Breslow thickness** (the depth of the tumor measured in millimeters from the top of the skin layer) and the presence of ulceration.
🔪 Surgical Interventions
For localized melanoma, surgical removal is the primary and curative treatment.
- Wide Local Excision (WLE): Removal of the tumor along with a safety margin of surrounding healthy tissue (ranging from 0.5 cm to 2 cm depending on tumor thickness) to prevent local recurrence.
- Sentinel Lymph Node Biopsy (SLNB): Recommended for intermediate-thickness melanomas (typically Breslow thickness > 0.8 mm or < 0.8 mm with ulceration) to determine if the cancer has spread to the nearest drainage lymph nodes.
💊 Immunotherapy & Targeted Drugs
Patients with lymph node involvement (Stage III) or distant metastasis (Stage IV) benefit significantly from systemic adjuvant or therapeutic drugs.
Checkpoint Inhibitor Immunotherapies
- Anti-PD-1 Antibodies: Pembrolizumab (Keytruda) and Nivolumab (Opdivo) block the PD-1 receptor on T-cells, enabling the patient's own immune system to recognize and attack melanoma cells.
- Anti-CTLA-4 Antibodies: Ipilimumab (Yervoy) is often combined with anti-PD-1 agents for superior efficacy in metastatic stages.
Targeted Kinase Inhibitors
- BRAF & MEK Inhibitors: For the 50% of patients whose tumors harbor a **BRAF V600 mutation**. Combination therapies like Dabrafenib (Tafinlar) + Trametinib (Mekinist) or Encorafenib + Binimetinib block the mutated cell-growth pathway directly.
📊 Breslow Thickness & Excision Margins
Breslow thickness is the most critical prognostic factor for localized melanoma, determining both the stage and the required surgical safety margins:
- Melanoma in situ (Stage 0): Confined to the epidermis. Requires a **0.5 cm** surgical margin. Sentinel lymph node biopsy is not indicated.
- Thin Melanoma (≤ 1.0 mm depth): Stage IA or IB. Requires a **1.0 cm** surgical margin. SLNB is considered if thickness is ≥ 0.8 mm or if ulceration is present.
- Intermediate Melanoma (1.01 mm - 2.0 mm depth): Stage IB or IIA. Requires a **1.0 to 2.0 cm** surgical margin. Sentinel lymph node biopsy is routinely recommended.
- Thick Melanoma (> 2.0 mm depth): Stage IIB or IIC. Requires a **2.0 cm** surgical margin. High probability of microscopic lymph node spread; SLNB is strongly recommended.
🔬 Active Clinical Trials
Clinical trials are currently evaluating personalized mRNA cancer vaccines, tumor-infiltrating lymphocyte (TIL) cellular therapies, and novel antibody-drug conjugates.
Comparing Pembrolizumab combined with a personalized mRNA cancer vaccine against Pembrolizumab alone in adjuvant melanoma.
Key Inclusion: Resected Stage IIB, IIC, III, or IV cutaneous melanoma; surgical resection completed within 13 weeks; tumor tissue available for mRNA vaccine sequencing.Evaluating the safety and efficacy of autologous TIL infusion (Lifileucel) in patients with advanced melanoma.
Key Inclusion: Unresectable or metastatic Stage III/IV melanoma, progressed after prior anti-PD-1 therapy (and BRAF inhibitor if BRAF mutant), and at least one resectable lesion for TIL harvest.Testing a novel bispecific antibody targeting both PD-1 and LAG-3 checkpoint receptors in advanced disease.
Key Inclusion: Histologically confirmed advanced or metastatic melanoma, no prior systemic checkpoint immunotherapy, and measurable disease by RECIST 1.1.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Melanoma, take these proactive steps:
- Confirm BRAF Mutation Status: Discuss with your oncologist if your tumor has been tested for BRAF mutations, which determines if targeted oral drugs can be used.
- Review Surgical Margin Plan: Discuss the planned excision margins and whether a Sentinel Lymph Node Biopsy is recommended based on your pathology report.
- Schedule Full-Body Skin Checks: Establish a routine of professional skin exams every 3 to 6 months with a dermatologist.
- Perform Monthly Self-Exams: Inspect your skin monthly under good lighting, using mirrors to examine hard-to-see areas like the back and back of thighs.
❓ Patient FAQ
Q: Does melanoma only occur on sun-exposed skin?
A: No. While UV exposure is a major risk factor, melanoma can occur anywhere on the body, including areas that rarely see the sun (like soles of the feet, under nails - acral lentiginous melanoma, and mucous membranes).
Q: What is the prognosis for early-stage melanoma?
A: Very high. Localized melanoma (Stage I) has a 5-year survival rate of over 99% when detected and surgically removed early, highlighting the vital importance of regular skin checks.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.